<?xml version="1.0" encoding="UTF-8"?>
<p>Recently, on 1 May 2020, the U.S. Food and Drug Administration issued an emergency use authorization of remdesivir for COVID-19 patients. Adverse effects of remdesivir include nausea, vomiting, and liver transaminase elevations. As the used vehicle is cyclodextrin, there is a risk of the potential toxic accumulation of this substance in patients with renal impairment. Remdesivir may be used for pregnant women and children only as compassionate drug use. Remdesivir is under investigation as one of the four arms in the “Solidarity” clinical trial, and its outcome in COVID-19 has been so far described only in case series [
 <xref rid="B21-pharmaceuticals-13-00096" ref-type="bibr">21</xref>,
 <xref rid="B22-pharmaceuticals-13-00096" ref-type="bibr">22</xref>]. Several clinical trials are currently investigating the drug; see 
 <xref rid="pharmaceuticals-13-00096-t001" ref-type="table">Table 1</xref>.
</p>
